Acrivon Therapeutics (ACRV) Q2 2024 earnings summary

Executive summary

• Lead candidate ACR-368 advanced in a registrational Phase 2 trial for multiple solid tumors, showing a 50% confirmed objective response rate in OncoSignature-positive ovarian and endometrial cancer patients as of April 2024.

• FDA granted Fast Track and Breakthrough Device designations for ACR-368 and its companion diagnostic test.

• Preclinical pipeline includes ACR-2316, a WEE1/PKMYT1 inhibitor, on track for IND filing in Q3 2024, and a cell cycle program with an undisclosed target advancing toward candidate nomination in 2025.

• AP3 platform leverages generative AI and proteomics for precision oncology, targeting high unmet need cancers.

• $123.8 million to $130 million raised in oversubscribed private placement financing at a premium, strengthening cash position.

Financial highlights

• Net loss for Q2 2024 was $18.8 million, compared to $13.9 million in Q2 2023; net loss for the first six months of 2024 was $35.3 million, up from $26.7 million year-over-year.

• Research and development expenses rose to $15.0 million in Q2 2024 from $10.5 million in Q2 2023, driven by clinical trial progression and increased headcount.

• General and administrative expenses increased to $6.4 million in Q2 2024 from $5.0 million in Q2 2023, mainly due to higher payroll and stock-based compensation.

• Cash, cash equivalents, and investments totaled $220.4 million as of June 30, 2024, expected to fund operations into the second half of 2026.

Outlook and guidance

• Existing cash and investments are expected to fund operations into the second half of 2026.

• Additional ACR-368 clinical data to be presented at ESMO in September 2024.

• Phase 1 clinical study of ACR-2316 planned to initiate in Q4 2024.

• New drug discovery program for an undisclosed target advancing toward candidate nomination in 2025.

• Additional funding will be required to support long-term growth and development plans.